Table 2.
Treatment characteristics in 10 patients with 15 recurrent cranial medulloblastomas.
| Characteristics | Entire Cohort | Pediatric | Adult | Statistical Significance (p Values) |
|---|---|---|---|---|
| # Tumors per patient | 0.4 | |||
| Mean | 1.5 | 1.6 | 1 | |
| Median | 1 | 1 | 1 | |
| Range | 1–4 | 1–4 | 1 | |
| Age at Treatment, yrs | ||||
| Mean | 14.3 | 12.4 | 27 | <0.001 |
| Median | 13 | 12 | 27 | |
| Range | 9–29 | 9–16 | 25–29 | |
| Interval between Diagnosis to SRS, mo | ||||
| Mean | 42.7 | 45.5 | 24.5 | |
| Median | 30 | 39 | 24.5 | 0.4 |
| Range | 12–108 | 12–108 | 24–25 | |
| Target Tumor Volume, cc | ||||
| Mean | 2.7 | 2.9 | 1.5 | 0.51 |
| Median | 1.9 | 1.8 | 1.5 | |
| Range | 0.02–8.7 | 0.02–8.7 | 0.5–2.5 | |
| Margin Dose, Gy | ||||
| 1 Fraction | 0.8 | |||
| Mean | 17.8 | 17.8 | 18 | |
| Median | 18 | 18 | 18 | |
| Range | 14–20 | 14–20 | 18 | |
| 2 Fractions | ||||
| Mean | 20 | 20 | N/A | |
| Median | 20 | 20 | N/A | |
| Range | 20 | 20 | N/A | |
| 3 Fractions | ||||
| Mean | N/A | N/A | N/A | |
| Median | N/A | N/A | N/A | |
| Range | N/A | N/A | N/A | |
| 4 Fractions | ||||
| Mean | N/A | N/A | N/A | |
| Median | N/A | N/A | N/A | |
| Range | N/A | N/A | N/A | |
| 5 Fractions | ||||
| Mean | 25 | 25 | N/A | |
| Median | 25 | 25 | N/A | |
| Range | 25 | 25 | N/A | |
| Maximum Dose, Gy | ||||
| 1 Fraction | 0.9 | |||
| Mean | 23.3 | 23.1 | 24.2 | |
| Median | 24.2 | 24.2 | 24.2 | |
| Range | 19.7–25 | 19.7–25 | 24.2–24.3 | |
| 2 Fractions | ||||
| Mean | 30.8 | 65 | N/A | |
| Median | 30.8 | 65 | N/A | |
| Range | 30.8 | 65 | N/A | |
| 3 Fractions | ||||
| Mean | N/A | N/A | N/A | |
| Median | N/A | N/A | N/A | |
| Range | N/A | N/A | N/A | |
| 4 Fractions | ||||
| Mean | N/A | N/A | N/A | |
| Median | N/A | N/A | N/A | |
| Range | N/A | N/A | N/A | |
| 5 Fractions | ||||
| Mean | 35.7 | 70 | N/A | |
| Median | 35.7 | 70 | N/A | |
| Range | 35.7 | 70 | N/A | |
| # Fraction | ||||
| Mean | 1.3 | 1.4 | 1 | |
| Median | 1 | 1 | 1 | 0.6 |
| Range | 1–5 | 1–5 | 1 | |
| BED, Gy | ||||
| Mean | 118.1 | 117 | 126 | |
| Median | 126 | 126 | 126 | 0.7 |
| Range | 66.7–153.3 | 66.7–153.3 | 126 | |
| SFED | ||||
| Mean | 17.2 | 17.1 | 18 | |
| Median | 18 | 18 | 18 | 0.6 |
| Range | 12.7–20 | 12.7–20 | 18 | |
| EQD2 | ||||
| Mean | 70.8 | 70.2 | 75.6 | |
| Median | 75.6 | 75.6 | 75.6 | 0.7 |
| Range | 40–92 | 40–92 | 75.6 | |
| Isodose Line, % | ||||
| Mean | 74.9 | 74.9 | 74.5 | 0.9 |
| Median | 75 | 75 | 74.5 | |
| Range | 65–81 | 65–81 | 74–75 | |
| Follow Up, mo | ||||
| Mean | 35.6 | 36.5 | 29.5 | 0.6 |
| Median | 39 | 39 | 29.5 | |
| Range | 6–78 | 6–78 | 9–50 |
#, number; BED, biologically effective dose; SFED, single-fraction equivalent dose; EQD2, equivalent total doses in 2-Gy fractions; N/A, not applicable; cc, cubic centimeter; Gy, Gray; mo, months; yrs, years.